Condition: Metastatic Non-small Cell Lung Cancer With MTAP Deletion · Sponsor: Bristol-Myers Squibb
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Alaska Oncology and Hematology | Anchorage, Alaska, United States | Recruiting |
| Mayo Clinic in Arizona - Phoenix | Phoenix, Arizona, United States | Recruiting |
| University of Arizona Cancer Center | Tucson, Arizona, United States | Recruiting |
| Highlands Oncology Group | Springdale, Arkansas, United States | Recruiting |
| Local Institution - 0497 | Los Alamitos, California, United States | Not Yet Recruiting |
| USC/Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Local Institution - 0444 | Los Angeles, California, United States | Withdrawn |
| Local Institution - 0606 | Newark, Delaware, United States | Withdrawn |
| Helios Clinical Research - Fort Lauderdale | Fort Lauderdale, Florida, United States | Recruiting |
| Mayo Clinic in Florida | Jacksonville, Florida, United States | Recruiting |
| Local Institution - 0430 | St. Petersburg, Florida, United States | Withdrawn |
| Local Institution - 0523 | Tampa, Florida, United States | Not Yet Recruiting |
+ 306 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07063745